Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSS39 · 1 trial · 1 indication
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
| Arm | Type | Description |
|---|---|---|
| group 1 | EXPERIMENTAL | Low-dose Group |
| group 2 | EXPERIMENTAL | high dose Group |
| Name | Type | Description |
|---|---|---|
| SSS39 | DRUG | Single oral administration of SSS39 |
Inclusion Criteria: * 1\. Healthy subjects aged 18-45 years old (including boundary values), regardless of gender; * 2\. Subjects voluntarily participate in clinical trials and sign informed consent; * 3\. Male weight ≥50 kg, female weight ≥45 kg, body mass index (BMI) between 19-28 kg/m2 (includin...
SSS39 is an investigational small molecule being developed by Sunshine Biopharma Inc. (NASDAQ: SBFM). It is currently in Phase 1 clinical development, with a study evaluating its safety, tolerability, and pharmacokinetics as an injection in healthy Chinese subjects.
SSS39 is being studied for safety and tolerability in healthy volunteers. The ongoing Phase 1 trial is designed to evaluate the drug's safety, tolerability, and pharmacokinetics when administered as an injection, with a focus on healthy Chinese subjects.
SSS39 is being developed by Sunshine Biopharma Inc., a company publicly traded on NASDAQ under the ticker symbol SBFM. The company is conducting a Phase 1 clinical trial of SSS39 in healthy volunteers.
SSS39 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. A Phase 1 trial is currently enrolling participants by invitation to assess its safety, tolerability, and pharmacokinetics.
SSS39 is being evaluated in a single Phase 1 clinical trial registered as NCT07057726. This randomized, double-blind, controlled study is enrolling 48 healthy Chinese subjects aged 18 years and older to assess the safety, tolerability, and pharmacokinetics of SSS39 injection.
SSS39 is a distinct investigational small molecule developed by Sunshine Biopharma Inc. No alternative names for SSS39 have been disclosed in the clinical trial registration. The drug is being studied under its current name in the ongoing Phase 1 trial.